English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The efficacy of fluralaner, formulated as a chewable tablet (Bravecto™) or topical solution (Bravecto™ Spot-on Solution), was evaluated against naturally acquired  Sarcoptes scabiei  var.  canis  infestation in dogs.    Methods  The study was performed in privately-owned dogs naturally infested with  S. scabiei  var.  canis.  All dogs living in the same household as the infested dog were enrolled into one of 3 groups (2 fluralaner treated and 1 negative control). All dogs within one household were administered the same treatment, with one dog per household included in further observations and assessments. In total, 29 dogs confirmed positive for sarcoptic mange were included. On Day 0, all dogs in group 1 ( n  = 9) were treated once orally with fluralaner at a minimum dose of 25 mg/kg body weight; all dogs in group 2 ( n  = 11) were treated once topically with fluralaner at a dose of 25 mg/kg body weight; and dogs in group 3 ( n  = 9) were treated once topically with saline solution.  Sarcoptes scabiei  var.  canis  mites on each dog were counted before treatment and at 4 weeks after treatment in deep skin scrapings (~4 cm 2 ) from 5 different body areas. Clinical signs of infestation (i.e. erythematous papules; casts, scales and crusts; body areas with hair loss) and pruritus were recorded at the same time points.    Results  Single oral or topical treatment with fluralaner resulted in a 100 % reduction in mite counts post-treatment (group 1:  P  = 0.0009 and group 2:  P  = 0.0011). Resolution of clinical signs at four weeks post-treatment was variable, with improvement observed for erythematous papules, casts and crusts, and pruritus. All fluralaner treated dogs showed an improvement in overall hair re-growth compared with pre-treatment observations.    Conclusion  Fluralaner administered either orally or topically to naturally infested dogs eliminates  Sarcoptes scabiei  var.  canis  mites and improves clinical signs over a 4-week observation period.

parasites and vectors

Efficacy of fluralaner administered either orally or topically for the treatment of naturally acquired Sarcoptes scabiei var. canis infestation in dogs